エピソード

  • S1E6 - SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action

    S1E6 - SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action
    2021/05/07
    Visit http://morningcommutepodcast.com/SGLT2inhibitors6 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, Dr. James Januzzi and Dr. Silvio Inzucchi discuss the surge in collaboration between primary care physicians, endocrinologists, and cardiologists and the groundswell of cardiometabolic clinics. They attribute this to cardiologists moving beyond the so-called glucocentric view and focusing on how diabetes therapies might help reduce cardiovascular risk as well. Drs. Januzzi and Inzucchi will also discuss the recent guidelines that now incorporate sodium-glucose cotransporter 2 (SGLT-2) inhibitors into clinical pathways.
    続きを読む 一部表示
    24 分
  • S1E5 - SGLT-2 Inhibitors Morning Commute: The Heart Failure Connection

    S1E5 - SGLT-2 Inhibitors Morning Commute: The Heart Failure Connection
    2021/05/07

    Visit http://morningcommutepodcast.com/SGLT2inhibitors5 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. James Januzzi and Dr. Silvio Inzucchi discuss how sodium-glucose cotransporter 2 (SGLT-2) inhibitors evolved from treatments for type 2 diabetes mellitus (T2DM) to key treatments for patients with heart failure. Drs. Januzzi and Inzucchi look at the pivotal trials that thrust these treatments into the heart failure treatment limelight.
    続きを読む 一部表示
    24 分
  • S1E4 - SGLT-2 Inhibitors Morning Commute: Widening Benefit

    S1E4 - SGLT-2 Inhibitors Morning Commute: Widening Benefit
    2021/05/07

    Visit http://morningcommutepodcast.com/SGLT2inhibitors4 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. James Januzzi and Dr. Silvio Inzucchi will discuss SGLT-2 inhibition in cardiovascular risk reduction by taking a look at some of the pivotal clinical trial data.
    続きを読む 一部表示
    25 分
  • S1E3 - SGLT-2 Inhibitors Morning Commute: Optimizing Benefit in CKD Management

    S1E3 - SGLT-2 Inhibitors Morning Commute: Optimizing Benefit in CKD Management
    2021/02/27

    Visit http://morningcommutepodcast.com/SGLT2inhibitors3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will focus on chronic kidney disease (CKD) in patients with or without diabetes and treatment with sodium-glucose cotransporter 2 (SGLT-2) inhibitors. The bottom line is, how should these treatments be incorporated into clinical practice?
    続きを読む 一部表示
    25 分
  • S1E2 - SGLT-2 Inhibitors Morning Commute: CKD Benefit in Diabetic and Non-Diabetic Patients

    S1E2 - SGLT-2 Inhibitors Morning Commute: CKD Benefit in Diabetic and Non-Diabetic Patients
    2021/02/27

    Visit http://morningcommutepodcast.com/SGLT2inhibitors2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss clinical trial data that look at new directions for the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, particularly how they benefit patients with chronic kidney disease (CKD).
    続きを読む 一部表示
    24 分
  • S1E1 - SGLT-2 Inhibitors Morning Commute: A Mechanistic Explanation of Renal Benefit

    S1E1 - SGLT-2 Inhibitors Morning Commute: A Mechanistic Explanation of Renal Benefit
    2021/02/27

    Visit http://morningcommutepodcast.com/SGLT2inhibitors1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will be discussing sodium-glucose cotransporter 2 (SGLT-2) inhibitors and their role beyond glycemic control. What are the mechanisms and renal benefit of SGLT-2 inhibitors?
    続きを読む 一部表示
    27 分